Table 2 Clinical characteristics of patients at baseline and after 24 and 48 weeks of adalimumab treatment
Variable | Week 0 | Week 24 | P | Week 48 | P |
|---|---|---|---|---|---|
DAS 28 | 5.4 ± 1.3 | 3.6 ± 1.2 | <0.01 | 2.7 ± 0.9 | <0.01 |
Tender joint count | 12.4 ± 4.7 | 5.1 ± 3.5 | <0.01 | 4.9 ± 3.5 | <0.01 |
Swollen joint count | 10.4 ± 3.8 | 3.2 ± 3.4 | <0.01 | 3.12 ± 3.4 | <0.01 |
ESR (mm/h) | 35 ± 17 | 26 ± 16 | <0.01 | 24 ± 15 | <0.01 |
CRP (mg/dl) | 42 ± 22.7 | 21 ± 15.2 | <0.01 | 15 ± 14.8 | <0.01 |
Anti-CCP (AU)a | 116.9 ± 43.6 | 100.5 ± 46.5 | <0.01 | 78.5 ± 43.9 | <0.01 |
RF (IU) | 121.7 ± 120.6 | 81 ± 90 | <0.01 | 70.2 ± 82.7 | <0.01 |